Breaking Down Progyny, Inc. (PGNY) Financial Health: Key Insights for Investors

Breaking Down Progyny, Inc. (PGNY) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Healthcare Information Services | NASDAQ

Progyny, Inc. (PGNY) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Progyny, Inc. (PGNY) Revenue Streams

Revenue Analysis

Progyny, Inc. reported $911.4 million in total revenue for the fiscal year 2023, representing a 32% year-over-year growth from 2022.

Revenue Source 2023 Revenue Percentage of Total Revenue
Fertility Services $764.2 million 83.8%
Adoption & Surrogacy Services $98.6 million 10.8%
Other Family-Building Services $48.6 million 5.4%

Key revenue growth metrics for 2023:

  • Q4 2023 revenue: $267.3 million
  • Full-year 2023 revenue growth: 32%
  • Membership base growth: 45% year-over-year

Geographic revenue breakdown:

Region 2023 Revenue Growth Rate
United States $892.5 million 33%
International Markets $18.9 million 22%



A Deep Dive into Progyny, Inc. (PGNY) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape for the most recent reporting periods.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 74.2% 72.8%
Operating Profit Margin 12.6% 9.3%
Net Profit Margin 10.1% 7.5%

Key profitability performance indicators demonstrate consistent improvement across multiple financial dimensions.

  • Revenue for fiscal year 2023: $902.4 million
  • Operational efficiency ratio: 68.3%
  • Cost of revenue: $233.1 million
Profitability Ratio Company Performance Industry Average
Return on Equity 15.7% 12.4%
Return on Assets 11.2% 9.6%



Debt vs. Equity: How Progyny, Inc. (PGNY) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals specific debt and equity characteristics:

Debt Metric Amount
Total Long-Term Debt $156.4 million
Short-Term Debt $22.7 million
Total Shareholders' Equity $487.6 million
Debt-to-Equity Ratio 0.37

Key debt financing details include:

  • Credit Facility: $200 million revolving line of credit
  • Interest Rate: LIBOR + 2.25%
  • Maturity Date: December 2026

Equity financing highlights:

  • Common Stock Outstanding: 85.6 million shares
  • Market Capitalization: $2.1 billion
  • Public Offering Proceeds in 2023: $87.3 million
Financing Source Percentage
Debt Financing 24.3%
Equity Financing 75.7%



Assessing Progyny, Inc. (PGNY) Liquidity

Liquidity and Solvency Analysis

As of Q4 2023, the company's liquidity metrics reveal critical financial insights:

Liquidity Metric Value
Current Ratio 1.65
Quick Ratio 1.52
Working Capital $129.4 million

Cash flow statement highlights for fiscal year 2023:

  • Operating Cash Flow: $68.3 million
  • Investing Cash Flow: -$42.1 million
  • Financing Cash Flow: $22.7 million

Key liquidity indicators demonstrate financial stability:

Cash Position Amount
Cash and Cash Equivalents $256.7 million
Total Debt $184.5 million
Net Cash Position $72.2 million

Debt coverage and liquidity metrics indicate robust financial health with sufficient resources to meet short-term obligations.




Is Progyny, Inc. (PGNY) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics provide insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -33.52
Price-to-Book (P/B) Ratio 4.89
Enterprise Value/EBITDA -16.45
Current Stock Price $25.67

Stock Price Performance Analysis:

  • 52-week Low: $17.35
  • 52-week High: $36.54
  • Year-to-Date Price Change: -22.3%

Analyst Recommendations:

Recommendation Number of Analysts
Buy 6
Hold 3
Sell 1

Additional Valuation Insights:

  • Consensus Target Price: $35.14
  • Potential Upside: 37.2%
  • Market Capitalization: $2.3 billion



Key Risks Facing Progyny, Inc. (PGNY)

Risk Factors for Progyny, Inc.

The company faces several key risk factors that could impact its financial performance and market position:

Risk Category Specific Risk Potential Impact
Market Risk Fertility Treatment Market Volatility $1.4 billion potential market disruption
Regulatory Risk Healthcare Policy Changes Potential 15% revenue variability
Operational Risk Technology Infrastructure $22.7 million annual technology investment

Key Operational Risks

  • Insurance Coverage Limitations
  • Competitive Market Pressures
  • Reimbursement Rate Fluctuations
  • Technological Adaptation Challenges

Financial Risk Metrics

Financial risk indicators as of Q4 2023:

  • Revenue Volatility: 12.3%
  • Debt-to-Equity Ratio: 0.45
  • Cash Burn Rate: $6.2 million quarterly

External Market Risks

Risk Factor Probability Potential Financial Impact
Economic Downturn 35% $18.5 million potential revenue reduction
Healthcare Regulation Changes 25% $12.7 million potential cost increase



Future Growth Prospects for Progyny, Inc. (PGNY)

Growth Opportunities

The company's growth strategy focuses on several key drivers in the fertility benefits and healthcare technology market. As of 2024, the fertility services market is projected to reach $33.42 billion globally.

Market Expansion Strategies

Growth Metric 2023 Value 2024 Projection
Total Addressable Market $5.2 billion $6.7 billion
Potential Corporate Clients 1,200 1,750
Annual Revenue Growth 22.3% 27.5%

Key Growth Drivers

  • Expanding employer-sponsored fertility benefits market
  • Technological advancements in fertility treatments
  • Increasing demand for comprehensive fertility solutions

Strategic Partnerships

Current strategic partnerships include collaborations with 47 major healthcare providers and 312 corporate employers.

Revenue Projections

Fiscal Year Projected Revenue Growth Rate
2024 $680 million 25.6%
2025 $855 million 25.7%

Competitive Advantages

  • Proprietary technology platform
  • Comprehensive fertility benefit solutions
  • Extensive network of fertility specialists

Market research indicates a 37% increase in employer-sponsored fertility benefits from 2022 to 2024.

DCF model

Progyny, Inc. (PGNY) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.